RA Capital Management, an American investment firm based in Boston, led a £60m funding round in Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, with participation from Lightstone Ventures, Dementia Discovery, SV Health Investors, Data Collective VC and DHVC. “Our aim is to become a major player in the identification of novel targets and antibodies in the areas of neurodegeneration and cancer. The substantial financial commitment by this high-caliber group of US and European investors is a strong endorsement of our science and team,” Alex Leech, Alchemab CEO.